clinical trial · NCT07709910
A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis
Fujian Shengdi Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 382
Participants With Obesity and Knee OsteoarthritisRibupatide InjectionPlacebo
brief summary
The study is being conducted to evaluate the efficacy and safety of Ribupatide Injection in participants with obesity and knee osteoarthritis, and to explore its improvement on knee joint structure.
started
Jul 1, 2026
primary completion
Nov 1, 2028
completion
Dec 1, 2028
last updated
Jul 17, 2026
official title
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol